scholarly journals Melanoma-associated antigen expression and the efficacy of tyrosine kinase inhibitors in head and neck cancer

2015 ◽  
Vol 10 (2) ◽  
pp. 1211-1217 ◽  
Author(s):  
STEFAN HARTMANN ◽  
ROMAN C. BRANDS ◽  
NORA KÜCHLER ◽  
ANDREAS FUCHS ◽  
CHRISTIAN LINZ ◽  
...  
Keyword(s):  
Head And Neck Cancer ◽  
Tyrosine Kinase ◽  
Head And Neck ◽  
Tyrosine Kinase Inhibitors ◽  
Neck Cancer ◽  
Kinase Inhibitors ◽  
Antigen Expression

Spleen tyrosine kinase expression is correlated with human papillomavirus in head and neck cancer

Oral Oncology ◽  
2020 ◽  
Vol 101 ◽  
pp. 104529 ◽  
Author(s):  
Morgan Black ◽  
Farhad Ghasemi ◽  
Ren X. Sun ◽  
William Stecho ◽  
Alessandro Datti ◽  
...  
Keyword(s):  
Head And Neck Cancer ◽  
Human Papillomavirus ◽  
Tyrosine Kinase ◽  
Head And Neck ◽  
Neck Cancer ◽  
Spleen Tyrosine Kinase ◽  
Kinase Expression

Targeted Therapy in Combination with Chemotherapy in Recurrent and/or Metastatic Head and Neck Cancer

2010 ◽  
Vol 06 (01) ◽  
pp. 43
Author(s):  
Pol Specenier ◽  
Jan B Vermorken ◽  
◽  
Keyword(s):  
Monoclonal Antibodies ◽  
Tyrosine Kinase ◽  
Head And Neck ◽  
Tyrosine Kinase Inhibitors ◽  
Kinase Inhibitors ◽  
Cell Cancer ◽  
Growth Factor Receptor ◽  
Phase Iii ◽  
Platinum Based Chemotherapy ◽  
Pathway Inhibition

Two epidermal growth factor receptor (EGFR)-targeting strategies are used in recurrent and/or metastatic squamous cell cancer of the head and neck (SCCHN): monoclonal antibodies and small-molecule tyrosine kinase inhibitors. Thus far, the monoclonal antibody cetuximab has been studied in most detail. Based on the results of two randomised phase III trials, cetuximab in combination with platinum-based chemotherapy should be considered the new standard first-line regimen for patients with recurrent and/or metastatic disease for whom a platinum-based regimen regimen is considered the best treatment option. Other EGFR-directed monoclonal antibodies are under investigation. The role of EGFR tyrosine kinase inhibitors (TKIs) in SCCHN is less well established and early data on other targeted agents have also been disappointing thus far. Dual pathway inhibition may overcome resistance to single pathway inhibition.

S115 The Receptor Tyrosine Kinase c-MET Is Mutated in Head and Neck Cancer and Is a Promising Novel Target

2006 ◽  
Vol 132 (8) ◽  
pp. 864
Author(s):  
T. Y. Seiwert ◽  
A. J. Klein-Szanto ◽  
R. Jagadeeswaran ◽  
M. Tretiakova ◽  
L. Martin ◽  
...  
Keyword(s):  
Head And Neck Cancer ◽  
Tyrosine Kinase ◽  
Head And Neck ◽  
Neck Cancer ◽  
Receptor Tyrosine Kinase ◽  
Kinase C ◽  
Novel Target
Sign in / Sign up

Export Citation Format

Share Document